In recent years, there has been tremendous growth in new diagnostic information, pharmacological and neurosurgical treatments for neurological disease, as well as a greater understanding of brain function. Our news section informs you of ongoing topics with a potential worldwide influence. In addition to this section, we inform through our social media platforms to keep connect with our member more easier than before.
Our subcategories on News include:
3 Mar 2026
12 Mar 2026
3 Mar 2026
12 Mar 2026
Systematic review and meta-analysis aimed to determine the long-term prevalence in COVID-19 survivors of fourteen specific NMDs and related symptoms.
12 Mar 2026
Vol. 483, April 2026 now available
11 Mar 2026
A new review evaluates why monoclonal antibodies (mAbs) targeting α-synuclein have so far failed to demonstrate clinical benefit in Parkinson’s disease (PD), despite strong preclinical promise. Analysing data from five randomised controlled trials, the authors assess safety, pharmacokinetics, central nervous system exposure, and target engagement.